44 / 86
Most Common Post-Study Therapies
Post-study systemic therapies
Eribulin (n=228)
n (%)
Dacarbazine (n=224)
n (%)
Any
158 (69.3)
141 (62.9)
Dacarbazine
78 (34.2)
17 (7.6)
Doxorubicin
26 (11.4)
16 (7.1)
Gemcitabine
48 (21.1)
47 (21.0)
Ifosfamide
27 (11.8)
22 (9.8)
Pazopanib
58 (25.4)
62 (27.7)
Trabectedin
36 (15.8)
27 (12.1)
Eribulin
3 (1.3)
6 (2.7)
Administration of post-study therapies (including surgery and radiotherapy) was comparable between the 2
arms, except for the higher number of patients in the eribulin arm who received post-study dacarbazine
Schöffski P, et al. Presented at ASCO 2015 Annual Meeting, Chicago IL, June 3-7, 2015:abstr LBA10502